|
|
|
|
|
Moclobemide
drug data and news
Moclobemide drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Moclobemide | ||
| Brand Names/Synonyms | Aurorix; CHEMBANK1633; HSDB 7180; Manerix; Moclaime; Moclamide; Moclobemid; Moclobemida [Inn-Spanish]; Moclobemide; Moclobemide [Usan:Ban:Inn]; Moclobemidum [Inn-Latin]; Modobemde | ||
| Indication | Depression | ||
| Sponsored links | Description | Not Available | |
| Pharmacology | Moclobemide belongs to a class of MAOI antidepressants known as reversible inhibitors of monoamine oxidase type-A (RIMAs). The primary role of monoamine oxidase MAO lies in the metabolism of and regulation of the levels of monoamines (serotonin, norepinephrine, and dopamine). Within neurons, MAO appears to regulate the levels of monoamines released upon synaptic firing. Since depression is associated with low levels of monoamines, the inhibition of MAO serves to ease depressive symptoms. RIMAs demonstrate transient inhibition of the substrate binding site of MAO-A as well as competitive displacement from this site by bioamines. The RIMAs are distinguished from the older monoamine oxidase inhibitors (MAOIs) by their selectivity and reversibility. | ||
| Mechanism Of Action | The mechanism of action of Moclobemide involves the selective, reversible inhibition of MAO-A. This inhibition leads to a decrease in the metabolism and destruction of monoamines in the neurotransmitters. This results in an increase in the monoamines, relieving depressive symptoms. | ||
| Moclobemide News (When available) |
MedPage Today, ...agents which have been shown to be effective in randomized trials include Prozac (fluoxetine) and the monoamine oxidase inhibitor Manerix (moclobemide). ... | ||
| Dosage Forms | TABLET | ||
| Drug_Category | Antidepressants; Antidepressants; ATC:N06AG02 | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | 4-chloro-N-(2-morpholin-4-ylethyl)benzamide | ||
| Chemical Formula | C13H17ClN2O2 | ||
| Molecular Weight | 268.739 g/mol | ||
| Smiles String | C1COCCN1CCNC(=O)C2=CC=C(C=C2)Cl | ||
| Melting Point | Not Available | ||
| Water Solubility | Not Available | ||
| State | Solid | ||
| LogP/Hphobicity | 1.298 | ||
| Isoelectric Point | Not Available | ||
| Biotransformation | Not Available | ||
| Half Life | 1.5 hours | ||
| Protein Binding [%] | ~50% | ||
| RxList Link | Not Available>RXlist | ||
| Sponsored links | |||
| Drug Reference | http://www.drugs.com/cons/Moclobemide.html | ||
| Drug Type | Approved Drug | ||
| Accession No | APRD00603 | ||
| CAS Registry Number | 71320-77-9 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | SID:65410 | ||
| PharmGKB ID | PA452615 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | 2243348 |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |